Keros Therapeutics (KROS) Free Cash Flow (2019 - 2025)
Keros Therapeutics' (KROS) quarterly Free Cash Flow came in at -$28.8 million in Q4 2025, up 37.71% YoY from -$20.9 million in Q4 2024, and down 736.74% on a QoQ basis from $4.5 million in Q3 2025.
Keros Therapeutics (KROS) Free Cash Flow (2019 - 2025) Analysis & Trends
Keros Therapeutics (KROS) has 7 years of Free Cash Flow data on file, last reported at -$28.8 million in Q4 2025.
- Quarterly Free Cash Flow rose 37.71% year-over-year to -$28.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $106.0 million (up 165.08% YoY) and the FY2025 annual result came in at $106.0 million, up 165.08% from the prior year.
- Free Cash Flow retreated to -$28.8 million in Q4 2025, from $4.5 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $160.6 million in Q1 2025 to a low of -$46.3 million in Q4 2024.
- A 5-year average of -$15.9 million and a median of -$25.0 million in 2022 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2023 — Free Cash Flow sank 2162.62% — and 2025, when it soared 458.58%.
- Tracing KROS's Free Cash Flow over 5 years: stood at -$19.7 million in 2021, then slipped by 9.03% to -$21.5 million in 2022, then dropped by 20.9% to -$26.0 million in 2023, then sank by 78.07% to -$46.3 million in 2024, then soared by 37.71% to -$28.8 million in 2025.
- The last three Free Cash Flow figures came in at -$28.8 million (Q4 2025), $4.5 million (Q3 2025), and -$30.3 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Keros Therapeutics | 217.61 Mn | -40.00 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -28.84 Mn |
| Dec 31, 2025 | -28.84 Mn |
| Sep 30, 2025 | 4.53 Mn |
| Sep 30, 2025 | 4.53 Mn |
| Jun 30, 2025 | -30.34 Mn |
| Jun 30, 2025 | -30.34 Mn |
| Mar 31, 2025 | 160.61 Mn |
| Mar 31, 2025 | 160.61 Mn |
| Dec 31, 2024 | -46.30 Mn |
| Dec 31, 2024 | -46.30 Mn |
| Sep 30, 2024 | -30.89 Mn |
| Sep 30, 2024 | -30.89 Mn |
| Jun 30, 2024 | -40.83 Mn |
| Jun 30, 2024 | -40.83 Mn |
| Mar 31, 2024 | -44.79 Mn |
| Mar 31, 2024 | -44.79 Mn |
| Dec 31, 2023 | -26.00 Mn |
| Dec 31, 2023 | -26.00 Mn |
| Sep 30, 2023 | -34.53 Mn |
| Sep 30, 2023 | -34.53 Mn |